NR0B2 and breast carcinoma: Here, we showed that sorafenib did not efficiently increase SHP-1 activity and did not effectively inhibit p-STAT3 in several breast cancer cell lines such as MDA-MB-231 and MDA-MB-468 cells (Figure 2) or in MDA-MB-468 xenograft tumors (Figure 5A), as compared with sorafenib analogues SC-1 and SC-43.